RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: 2-Aminopurine; Famciclovir

Criteria

Inclusion Criteria:

• • Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months.

• Patients with active HSV-2 or HSV-1 infection as confirmed by Polymerase Chain Reaction (PCR).

• Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes

Exclusion Criteria:

• • Female patients who are pregnant or breast-feeding.

• Current, history or suspicion of liver disease or kidney disease.

• HIV infected (as confirmed by positive HIV serology).

Other protocol-defined inclusion/exclusion criteria may apply.